National Leaders in Allogeneic Transplantation
*For the eleventh consecutive year (2009-19), NH-BMT achieved survival outcomes that significantly exceeded the expected range as reported in the Center for International Blood and Marrow Transplant Research Final 2019 Transplant Center Specific Survival Report, December 16, 2019 and from reported outcome data from Be The Match®.
Data was reported in the Center for International Blood and Marrow Transplant Research Final 2020 Transplant Center Survival Report and from Be The Match®.
THE NORTHSIDE DIFFERENCE
- Only attending BMT physicians take call after hours and on weekends.
- All BMT physicians focus on clinical patient care year-round.
- Outpatient based allogeneic transplant program that has shown to improve survival outcomes.
- Dedicated specialty designed 56-bed inpatient HEPA-filtered unit.
- High ratio of BMT trained pharmacists-to-patients.
- Outstanding re-accreditation with the Foundation of Accreditation for Cellular Therapy (FACT) with no clinical deficiencies for the last six consecutive tri-annual inspections.
One hundred seventy adult and pediatric transplant centers were included in the analysis of patients who received their first allogeneic transplant between January 1, 2015 and December 31, 2017 using unrelated or related donors and who had reported follow-up. The one-year survival of patients transplanted at Northside was 80.8%.
Northside was the ONLY adult BMT programs in the U.S. that achieved survival outcomes that significantly exceeded their expected survival rate for the last 12 consecutive reporting cycles, is the largest Allogenic program in Georgia, and the ONLY transplant center to exceed survival outcomes.
One hundred seventy two adult and pediatric transplant centers were included in the analysis. Survival information includes only patients who received their first allogeneic transplant between January 1, 2016 and December 31, 2018 using unrelated or related donors and who had reported follow-up.The one-year survival of patients transplanted at Northside was 80.8%. Specific transplant center information can be found at bethematch.org.
“The BMT Program at Northside is the largest allogeneic transplant program in Georgia,” said H. Kent Holland, M.D., medical director of The BMT Program at Northside Hospital Cancer Institute. “Our success is a direct reflection of the combined experience and expertise of the teams in our inpatient and outpatient BMT units, our stem-cell laboratory and blood donor center.”
Innovative treatments and research are major components of the BMT Program at Northside. Northside offers chimeric antigen receptor (CAR) T-cell therapy and other immunotherapy treatment options including novel clinical research trials.